Effects of PPAR Agonists on Weight and Lipid Profiles in Obese Mice
Author Information
Author(s): W. Wallace Harrington, S. Britt Christy, G. Wilson, Joan O. Milliken, Naphtali G. Binz, Jane C. Lobe, David R. Oliver, William C. Lewis, Michael M. Ignar
Primary Institution: GlaxoSmithKline Research, Research Triangle Park, NC, USA
Hypothesis
Activation of PPARα, PPARδ, and PPARγ will affect body weight, body composition, and serum lipid profiles in diet-induced obese mice.
Conclusion
PPARα and PPARδ activations are critical for effective weight loss induction, while PPARγ agonists lead to weight gain.
Supporting Evidence
- PPARα or PPARδ agonist treatment induced a slight decrease in fat mass.
- PPARγ agonist increased body weight and fat mass.
- Combination treatment with PPARα and δ agonists resulted in greater weight loss than either agent alone.
- PPARpan agonists induced significant and sustained reductions in body weight and fat mass.
Takeaway
This study looked at how different drugs that activate certain receptors in the body can help mice lose weight or gain weight, depending on the type of receptor activated.
Methodology
The study involved administering various PPAR agonists to diet-induced obese AKR/J mice and measuring their body weight, fat mass, food consumption, and serum chemistry over a four-week period.
Potential Biases
Potential bias in the selection of compounds and the interpretation of results due to the involvement of a pharmaceutical company.
Limitations
The study was conducted on a specific mouse strain, which may limit the generalizability of the findings to other populations.
Participant Demographics
Male AKR/J mice, diet-induced obesity model.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website